ZOLJA 2ml

GENERAL INFORMATION

Pharmacotherapeutic group Cardiac drugs. Other cardiological drugs. Thiazotic acid. ATC code C01E B23.

The pharmacological effect of thiazotic acid is due to its anti-ischemic, membrane-stabilizing, antioxidant and immunomodulatory effects.

The effect of the drug is realized by enhancing compensatory activation of anaerobic glycolysis and activation of oxidation processes in the Krebs cycle while maintaining the intracellular ATP pool. The presence of sulfur thiol, which is characterized by redox properties, and tertiary nitrogen, which binds excess hydrogen ions, in the structure of the thiazotic acid molecule, causes activation of the antioxidant system. The strong reducing properties of the thiol group cause a reaction with reactive oxygen species and lipid radicals. The reactivation of antiradical enzymes – superoxide dismutase, catalase and glutathione peroxidase – prevents the initiation of reactive oxygen species.

The effect of thiazotic acid leads to inhibition of lipid oxidation in the ischemic areas of the myocardium, reduction of myocardial sensitivity to catecholamines, prevention of progressive inhibition of cardiac contractility, stabilization and reduction of the myocardial necrosis and ischemia zone, respectively. Improvement of rheological properties of blood is achieved by activation of the fibrinolytic system. Improvement of myocardial metabolism, increase of its contractility, promotion of heart rhythm normalization allows to recommend thiazotic acid for treatment of patients with various forms of coronary heart disease.

Ingredients

active ingredient  thiazotic acid; 1 ml of the drug contains 25 mg of morpholinic salt of thiazotic acid, which is equivalent to 16.6 mg of thiazotic acid; excipient: water for injection.

Pharmaceutical form

Solution for injection.

Indications

In the complex treatment of coronary heart disease: angina pectoris, myocardial infarction, post-infarction cardiosclerosis; as an additional agent in the treatment of cardiac arrhythmias.
In the complex treatment of chronic hepatitis, alcoholic hepatitis, liver fibrosis and cirrhosis.

Dosage and administration

In myocardial infarction and unstable angina, the drug should be administered intravenously slowly at 4 ml of 25 mg/ml solution (100 mg) at a rate of 2 ml/min or intravenously drip at a rate of 20-30 drops per minute (4 ml of 25 mg/ml solution is diluted in 150 250 ml of 0.9% sodium chloride solution) or administered intramuscularly at 4 ml of 25 mg/ml solution (100 mg) 2-3 times a day. The course of treatment is 14 days. In case of angina pectoris, the drug should be administered intramuscularly at 4 ml of 25 mg/ml solution 2 times a day (daily dose – 200 mg). The course of treatment is 14 days.

In angina pectoris and post-infarction cardiosclerosis, the drug should be administered intramuscularly at 2 ml of 25 mg/ml solution 3 times a day. The course of treatment is 20-30 days.

In chronic hepatitis with severe process activity, the medicine should be administered intramuscularly in the first 5 days at 2 ml of 25 mg/ml solution (50 mg each) 2-3 times a day or intravenously slowly at 2 ml/min at 4 ml of 25 mg/ml solution (100 mg) once a day, or by drip at a rate of 20-30 drops per minute (2 ampoules of 25mg/ml solution are diluted in 150-250 ml of 0.9% sodium chloride solution).

From the 5th to the 20th day of therapy, the drug should be prescribed in tablet form (100mg 3 times daily).

In chronic hepatitis of minimal and moderate severity, the drug should be administered intramuscularly as 2 ml of 25 mg/ml solution 3 times daily. The course of treatment is 20-30 days.

In liver cirrhosis, the treatment course is 60 days. Treatment should be started with intramuscular injection of 2 ml of 25 mg/ml solution (50 mg) 3 times a day for 5 days, and then continue with tablets (100 mg 3 times a day).

Storage conditions Store in the original packaging at a temperature not exceeding 25 °C. Keep out of the reach of children.

Category of release  By prescription.